Chitra Singh

CSIR - Institute of Himalayan Bioresource Technology, Patampar, Himachal Pradesh, India

Are you Chitra Singh?

Claim your profile

Publications (5)5.91 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Silica-supported boric acid is found to be a green, efficient, and reusable catalyst for the synthesis of the title compounds under solvent-free conditions.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Silica-supported boric acid (H3BO3-SiO2) has been established as a green, efficient and recyclable catalyst for the synthesis of dihydropyrimidin-2-ones, bis(indolyl)methanes, and acetylation of alcohols, phenols, amines and thiols under solvent free conditions. The main features of the present method include clean reaction, mild conditions, low loading of environment friendly catalyst and easy workup procedure. The catalyst can be recycled at least five times without any significant loss in activity.
    Indian Journal of Chemistry Section B 01/2014; 53B(1):83-89. · 0.39 Impact Factor

  • ChemInform 08/2013; 44(34). DOI:10.1002/chin.201334231
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amide is the key functional group in organic and biological chemistry as it is present in many natural products of therapeutic importance, peptides and polymers. There is continuous exploration of methodologies that can facilitate the user to choose the method of its interest regarding the availability of substrates and high atom economy. In this review, the catalytic methods developed in the past decade mainly focusing on oxidative amidation of alcohols, aldehydes, ketones and esters, aminocarbonylation of aryl halides, alkanes, alkenes and alkynes using transition metals such as Ru, Rh, Fe, Cu, Co, Pd, Ag, Au, Ir and Zr based catalysts have been discussed to highlight the emerging methodologies and expansion of research. The methods developed for the conversion of nitriles and oximes to corresponding amides have also been discussed.
    Current Organic Synthesis 04/2013; 10(6):241-264. DOI:10.2174/1570179411310020003 · 2.12 Impact Factor
  • Neeraj Kumar · Upendra Sharma · Chitra Singh · Bikram Singh ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Thalidomide and its one analogue, lenalidomide (CC5103 or revlimid) are recently approved for the treatment of multiple myeloma. Multiple myeloma is characterized by an overproduction of malignant plasma cells in the bone marrow. The journey of thalidomide was started in 1956 when it was marketed as a non-barbiturate sedative agent. It was considered as a "wonder drug" that provided safe and sound sleep and hence, used to cure morning sickness in pregnant women. Later, in 1961, it was withdrawn from the world market due to its serious side effects, i.e., teratogenic activity. However, the recent decade has witnessed a true renaissance in interest in its broad biological activity. In particular, thalidomide was reevaluated and attracted significant attention due to its selective inhibitory activity of tumor necrosis factor-α (TNF-α), which is a clinically important activity against serious diseases such as rheumatoid arthritis, Crohn's disease, leprosy, AIDS, and various cancers. The comeback of thalidomide to the legitimate status of a marketed drug came in 1998 when it received FDA approval for the treatment of erythema nodosum leprosum (ENL). Recently, the drug has got FDA approval for the treatment of multiple myeloma. In the last few years, number of thalidomide analogues have been synthesized and are in clinical development as a class of immunomodulatory drugs. Among these, lenalidomide is more potent than thalidomide, and is also non-neurotoxic. It was shown in vitro studies to induce apoptosis or arrest growth even in resistant multiple myeloma cell lines, decrease binding of the cells to bone marrow stromal cells, and stimulate host natural killer cell immunity. It also inhibits tumour growth and decreases angiogenesis. Earlier reviews have described the pharmacological aspects of thalidomide and a review has focused only on synthetic aspect of thalidomide. However, review focusing on chemistry and metabolism and mechanism of biological activity is still lacking. In this review, we will concisely describe the therapeutic aspects, metabolism and synthesis of thalidomide.
    Current topics in medicinal chemistry 05/2012; 12(13):1436-55. DOI:10.2174/156802612801784407 · 3.40 Impact Factor